CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

Jan 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-01-20

Reporting Person: King Rachel K. (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-20	Common Stock	A	96250	$0.00	Acquired	452314	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-20	Employee Stock Option (right to buy)	$3.81	A	192500	Acquired	2031-01-19	Common Stock (192500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	129401	Indirect
Common Stock	45741	Indirect

Footnotes

F1: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date.

F3: These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 61,725 shares are held by The Rachel K. King 2016 GRAT.

F4: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.